• ABPI Website
  • Media
  • ABPI welcomes appointment of Madelaine McTernan as Head of HRT Taskforce

ABPI welcomes appointment of Madelaine McTernan as Head of HRT Taskforce

“Recent initiatives to improve access to HRT medicines are incredibly important in making sure that all women can get the treatment they need.

"We welcome the appointment of Madelaine McTernan to lead the work looking into the supply of HRT medicines. She brings a wealth of relevant experience from the private sector, and from Government, including her role as Director General of the Vaccines Taskforce. 

"The ABPI is working closely with our members, the NHSE Menopause Programme and the DHSC Medicines Supply Team to ensure that the right policies are in place to ensure all women can access HRT medicines.

"These important collaborations between industry, Government and the NHS will be vital in ensuring the best possible outcomes for patients.  We look forward to working closely with Ms McTernan in her new role.”

Richard Torbett, Chief Executive, ABPI

  • Supply
  • ABPI news

Last modified: 07 May 2024

Last reviewed: 07 May 2024

The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future. 

Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.